Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing

Anthrax vaccine adsorbed (AVA, BioThrax) was recently approved by the Food and Drug Administration (FDA) for a post-exposure prophylaxis (PEP) indication in adults 18–65 years of age. The schedule is three doses administered subcutaneous (SC) at 2-week intervals (0, 2, and 4 weeks), in conjunction w...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Vaccine
Prif Awduron: Stark, G.V., Sivko, G.S., VanRaden, M., Schiffer, J., Taylor, K.L., Hewitt, J.A., Quinn, C.P., Nuzum, E.O.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5130595/
https://ncbi.nlm.nih.gov/pubmed/27558619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2016.06.041
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg